Tetravalent rotavirus vaccine.

Area of Science:

• Vaccinology
• Pediatric Infectious Diseases
• Public Health

Background:

• Rotavirus gastroenteritis poses a significant global health challenge, impacting both developed and developing nations.
• The development of effective rotavirus vaccines is crucial for reducing childhood morbidity and mortality.

Purpose of the Study:

• To comprehensively review the clinical efficacy, safety, and pharmacoeconomic data of the rhesus-human reassortant rotavirus tetravalent vaccine (RRV-TV).
• To assess the potential impact of RRV-TV on healthcare costs and disease burden in infants and children.

Main Methods:

• A systematic literature search of MEDLINE (1990-1998) was performed to identify relevant studies.
• Included studies encompassed pharmacology, clinical trials (randomized, placebo-controlled), adverse effects, and pharmacoeconomic analyses.
• Bibliographies of retrieved articles were also reviewed to ensure comprehensive data collection.

Main Results:

• The RRV-TV vaccine demonstrated an 80% overall efficacy, particularly against severe rotavirus gastroenteritis.
• The vaccine is well-tolerated, with fever being the most common adverse effect after the first dose.
• Pharmacoeconomic evaluations suggest potential annual savings exceeding $1 billion in the US with universal RRV-TV adoption.

Conclusions:

• The RRV-TV vaccine is effective in preventing and reducing the incidence of rotavirus-induced gastroenteritis.
• Widespread provision of this vaccine to children globally can mitigate the disease's morbidity, mortality, and associated healthcare expenditures.